Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH). It is structurally similar to the thyroid hormone triiodothyronine and acts as an agonist of the thyroid hormone receptor beta (NR1A2).<\/p>\n
The most common side effects include diarrhea and nausea.<\/p>\n
NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation.<\/p>\n
For inquiries regarding availability, import process, or cost of REZDIFFRA (resmetirom):<\/strong> NEWS\/UPDATES<\/p>\n India Pharma Network acts solely as a facilitator for REZDIFFRA (resmetirom) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:<\/p>\n The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.<\/p>\n","protected":false},"excerpt":{"rendered":" Rezdiffra (resmetirom) is the first FDA-approved medication for adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) who have moderate to advanced liver scarring (fibrosis), used alongside diet and exercise to reduce liver fat, inflammation, and scarring by targeting liver thyroid hormone receptors. It’s an oral tablet taken once daily and works as a liver-directed therapy, though potential side effects include diarrhea, nausea, itching, and gallbladder issues, with ongoing studies confirming its long-term benefits.<\/p>\n
\nIndia Pharma Network (IPN)<\/strong> : Headquartered in New Delhi<\/strong>, with branch offices in Delhi, Gurugram, Mumbai, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur <\/strong>and Lucknow<\/strong>, IPN supports medicine imports across India on a Named Patient Import Basis<\/strong> and for personal use only<\/strong>.\u00a0Mobile\/WhatsApp:<\/strong> Mr. Tarun: +91 9891 296 838 | \u00a0Mr. Neeraj: +91 9811 747 774. Email:<\/strong> info@indianpharmanetwork.co.in<\/a><\/p>\n\n
Compliance & Disclaimer<\/h5>\n
\n
REZDIFFRA (resmetirom) \u2013 MASH, formerly NASH Therapy in India<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n REZDIFFRA<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n Resmetirom Tablets<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n \u2022 Tablets: 60 mg, 80 mg, and 100 mg<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Madrigal Pharmaceuticals<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n